OBI filed an Application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate, OBI-999, to TFDA

OBI Filed an Application of Investigational Device Exemption (IDE) for Phase II Cohort Expansion Human Clinical Trial for Globo H Antibody Drug Conjugate, OBI-999, to FDA

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the Company’s Board of Directors resolved to revise the Regulations for Issuance and Subscription of 2020 Employee Stock Options

Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the company’s Board of Directors resolved to change the date for 2021 annual shareholders’ meeting

Supplementary announcement of electronic voting shareholders’ complimentary gift for 2021 annual shareholders’ meeting

The Company’s Board of Directors resolved to issue employee stock options and the subscription rules

New appointment of Audit Committee member

Announcement of the Consolidated Financial Statements for the second quarter of 2021 were authorized for issuance by the Board of Directors

Patent of OBI-858 “Clostridium Botulinum toxin Type A composition, formulation and use thereof” was granted by the Taiwan Intellectual Property Office

Announcement to approve the lifting of non-competition restrictions for directors at the 2021 Annual General Meeting